FDA Grants Accelerated Approval to Infigratinib for Cholangiocarcinoma

On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to infigratinib for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

Read the FDA announcement.

Read the QED Therapeutics announcement.

Posted 6/1/2021